These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

133 related items for PubMed ID: 10623718

  • 1. Chemoreduction for retinoblastoma may prevent trilateral retinoblastoma.
    Shields CL, Shields JA, Meadows AT.
    J Clin Oncol; 2000 Jan; 18(1):236-7. PubMed ID: 10623718
    [No Abstract] [Full Text] [Related]

  • 2. Chemoreduction for retinoblastoma may prevent intracranial neuroblastic malignancy (trilateral retinoblastoma).
    Shields CL, Meadows AT, Shields JA, Carvalho C, Smith AF.
    Arch Ophthalmol; 2001 Sep; 119(9):1269-72. PubMed ID: 11545631
    [Abstract] [Full Text] [Related]

  • 3. Chemoreduction for retinoblastoma.
    Moll AC, Imhof SM, Schouten-van Meeteren AY, Boers M, van Leeuwen F, Hofman P.
    Arch Ophthalmol; 2003 Oct; 121(10):1513. PubMed ID: 14557204
    [No Abstract] [Full Text] [Related]

  • 4. Regarding chemoreduction for retinoblastoma and intracranial neoplasms.
    Meadows AT, Shields CL.
    Arch Ophthalmol; 2004 Oct; 122(10):1570-1; author reply 1571. PubMed ID: 15477483
    [No Abstract] [Full Text] [Related]

  • 5. Multifaceted chemotherapy for trilateral retinoblastoma.
    Dimaras H, Héon E, Doyle J, Strahlendorf C, Paton KE, Halliday W, Babyn P, Gallie BL, Chan HS.
    Arch Ophthalmol; 2011 Mar; 129(3):362-5. PubMed ID: 21402997
    [No Abstract] [Full Text] [Related]

  • 6. Trilateral retinoblastoma: potentially curable with intensive chemotherapy.
    Dunkel IJ, Jubran RF, Gururangan S, Chantada GL, Finlay JL, Goldman S, Khakoo Y, O'Brien JM, Orjuela M, Rodriguez-Galindo C, Souweidane MM, Abramson DH.
    Pediatr Blood Cancer; 2010 Mar; 54(3):384-7. PubMed ID: 19908299
    [Abstract] [Full Text] [Related]

  • 7. Histopathologic findings in eyes with retinoblastoma treated only with chemoreduction.
    Demirci H, Eagle RC, Shields CL, Shields JA.
    Arch Ophthalmol; 2003 Aug; 121(8):1125-31. PubMed ID: 12912690
    [Abstract] [Full Text] [Related]

  • 8. Post-chemoreduction cryptic optic nerve relapse in a patient with bilateral retinoblastoma.
    Shetye NG, Mataftsi A, Maeder P, Moulin AP, Gaillard MC, Balmer A, Popovic MB, Munier FL.
    Br J Ophthalmol; 2013 Feb; 97(2):233, 245-6. PubMed ID: 23172878
    [No Abstract] [Full Text] [Related]

  • 9. Development of new retinoblastomas after 6 cycles of chemoreduction for retinoblastoma in 162 eyes of 106 consecutive patients.
    Shields CL, Shelil A, Cater J, Meadows AT, Shields JA.
    Arch Ophthalmol; 2003 Nov; 121(11):1571-6. PubMed ID: 14609913
    [Abstract] [Full Text] [Related]

  • 10. Macular retinoblastoma managed with chemoreduction: analysis of tumor control with or without adjuvant thermotherapy in 68 tumors.
    Shields CL, Mashayekhi A, Cater J, Shelil A, Ness S, Meadows AT, Shields JA.
    Arch Ophthalmol; 2005 Jun; 123(6):765-73. PubMed ID: 15955977
    [Abstract] [Full Text] [Related]

  • 11. Cholesterosis following chemoreduction for advanced retinoblastoma.
    Gombos DS, Howes E, O'Brien JM.
    Arch Ophthalmol; 2000 Mar; 118(3):440-1. PubMed ID: 10721978
    [No Abstract] [Full Text] [Related]

  • 12. Retinoblastoma management: advances in enucleation, intravenous chemoreduction, and intra-arterial chemotherapy.
    Shields CL, Shields JA.
    Curr Opin Ophthalmol; 2010 May; 21(3):203-12. PubMed ID: 20224400
    [Abstract] [Full Text] [Related]

  • 13. Chemoreduction for retinoblastoma. Analysis of tumor control and risks for recurrence in 457 tumors.
    Shields CL, Mashayekhi A, Cater J, Shelil A, Meadows AT, Shields JA.
    Am J Ophthalmol; 2004 Sep; 138(3):329-37. PubMed ID: 15364213
    [Abstract] [Full Text] [Related]

  • 14. Trilateral retinoblastoma with pituitary-hypothalamic dysfunction.
    Dai S, Dimaras H, Héon E, Budning A, Doyle J, Halliday W, Drake J, Gallie BL, Chan HS.
    Ophthalmic Genet; 2008 Sep; 29(3):120-5. PubMed ID: 18766991
    [Abstract] [Full Text] [Related]

  • 15. Factors predictive of recurrence of retinal tumors, vitreous seeds, and subretinal seeds following chemoreduction for retinoblastoma.
    Shields CL, Honavar SG, Shields JA, Demirci H, Meadows AT, Naduvilath TJ.
    Arch Ophthalmol; 2002 Apr; 120(4):460-4. PubMed ID: 11934319
    [Abstract] [Full Text] [Related]

  • 16. Successful treatment of neonatal trilateral retinoblastoma.
    Bindlish R, LaRoche GR.
    J AAPOS; 1999 Dec; 3(6):376-8. PubMed ID: 10613584
    [Abstract] [Full Text] [Related]

  • 17. Trilateral retinoblastoma: a case report.
    Cho EY, Suh YL, Shin HJ.
    J Korean Med Sci; 2002 Feb; 17(1):137-40. PubMed ID: 11850605
    [Abstract] [Full Text] [Related]

  • 18. Evolution in regression patterns following chemoreduction for retinoblastoma.
    Palamar M, Thangappan A, Shields CL.
    Arch Ophthalmol; 2011 Jun; 129(6):727-30. PubMed ID: 21670339
    [Abstract] [Full Text] [Related]

  • 19. New insights into trilateral retinoblastoma.
    Singh AD, Shields CL, Shields JA.
    Cancer; 1999 Jul 01; 86(1):3-5. PubMed ID: 10391556
    [No Abstract] [Full Text] [Related]

  • 20. Resolution of iris neovascularization following chemoreduction of advanced retinoblastoma.
    Shields CL, Sun H, Manquez ME, Leahey A, Meadows AT, Shields JA.
    Arch Ophthalmol; 2006 Aug 01; 124(8):1196-7. PubMed ID: 16908826
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.